{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:11:39Z","timestamp":1781205099892,"version":"3.54.1"},"reference-count":54,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:00:00Z","timestamp":1594944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>The rapid emergence of antimicrobial resistance in Acinetobacter baumannii coupled with the dried pipeline of novel treatments has driven the search for new therapeutic modalities. Gram-negative bacteria have an extra outer membrane that serves as a permeability barrier for various hydrophobic and\/or large compounds. One of the popular approaches to tackle this penetration barrier is use of potentiators or adjuvants in combination with traditional antibiotics. This study reports the in vitro potential of an antimicrobial peptide tridecaptin M in combination with other antibiotics against different strains of A. baumannii. Tridecaptin M sensitized the bacteria to rifampicin, vancomycin, and ceftazidime. Further, we observed that a tridecaptin M and rifampicin combination killed the bacteria completely in 4 h in an ex vivo blood infection model and was superior to rifampicin monotherapy. The study also found that concomitant administration of both compounds is not necessary to achieve the antimicrobial effect. Bacteria pre-treated with tridecaptin M (for 2\u20134 h) followed by exposure to rifampicin showed similar killing as obtained for combined treatment. Additionally, this combination hampered the survival of persister development in comparison to rifampicin alone. These findings encourage the future investigation of this combination to treat severe infections caused by extremely drug-resistant A. baumannii.<\/jats:p>","DOI":"10.3390\/molecules25143255","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T07:31:28Z","timestamp":1595403088000},"page":"3255","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["In Vitro Evaluation of Antimicrobial Peptide Tridecaptin M in Combination with Other Antibiotics against Multidrug Resistant Acinetobacter baumannii"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3423-7105","authenticated-orcid":false,"given":"Manoj","family":"Jangra","sequence":"first","affiliation":[{"name":"Clinical Microbiology &amp; Bioactive Screening Laboratory, CSIR-Institute of Microbial Technology, Chandigarh 160 036, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2518-0015","authenticated-orcid":false,"given":"Vrushali","family":"Raka","sequence":"additional","affiliation":[{"name":"Clinical Microbiology &amp; Bioactive Screening Laboratory, CSIR-Institute of Microbial Technology, Chandigarh 160 036, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh 201 002, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemraj","family":"Nandanwar","sequence":"additional","affiliation":[{"name":"Clinical Microbiology &amp; Bioactive Screening Laboratory, CSIR-Institute of Microbial Technology, Chandigarh 160 036, India"},{"name":"Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh 201 002, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/07853890109002073","article-title":"Multidrug-resistant bacteria: Overcoming antibiotic permeability barriers of Gram-negative bacteria","volume":"33","author":"Savage","year":"2001","journal-title":"Ann. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17001","DOI":"10.1038\/nmicrobiol.2017.1","article-title":"Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria","volume":"2","author":"Masi","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: Past, Present, and Future","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jangra, M., Randhawa, H.K., Kaur, M., Srivastava, A., Maurya, N., Patil, P.P., Jaswal, P., Arora, A., Patil, P.B., and Raje, M. (2018). Purification, Characterization and in vitro Evaluation of Polymyxin A From Paenibacillus dendritiformis: An Underexplored Member of the Polymyxin Family. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.02864"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.chembiol.2018.01.005","article-title":"Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria","volume":"25","author":"Velkov","year":"2018","journal-title":"Cell Chem. Boil."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-019-1791-1","article-title":"A new antibiotic selectively kills Gram-negative pathogens","volume":"576","author":"Imai","year":"2019","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/CCM.0000000000000181","article-title":"The Deadly Impact of Extreme Drug Resistance in Acinetobacter baumannii","volume":"42","author":"Spellberg","year":"2014","journal-title":"Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e01110-18","DOI":"10.1128\/AAC.01110-18","article-title":"New Treatment Options against Carbapenem-Resistant Acinetobacter baumanniiInfections","volume":"63","author":"Isler","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: A systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit. Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ijantimicag.2019.02.016","article-title":"Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics\/pharmacodynamics in dose optimisation","volume":"53","author":"Lim","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12941-019-0319-8","article-title":"A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features","volume":"18","author":"Boral","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1128\/AAC.02927-15","article-title":"Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance","volume":"60","author":"Cheah","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of Infections Due to MDR Gram-Negative Bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1128\/AAC.00834-10","article-title":"Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production","volume":"54","author":"Moffatt","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e01083-19","DOI":"10.1128\/mBio.01083-19","article-title":"Dissecting Colistin Resistance Mechanisms in Extensively Drug-Resistant Acinetobacter baumannii Clinical Isolates","volume":"10","author":"Trebosc","year":"2019","journal-title":"mBio"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12941-019-0339-4","article-title":"Emergence of colistin resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli strains isolated from cancer patients","volume":"18","author":"Zafer","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Elbediwi, M., Li, Y., Paudyal, N., Pan, H., Xie, S., Rajkovic, A., Feng, Y., Fang, W., Rankin, S.C., and Yue, M. (2019). Global Burden of Colistin-Resistant Bacteria: Mobilized Colistin Resistance Genes Study (1980\u20132018). Microorganisms, 7.","DOI":"10.3390\/microorganisms7100461"},{"key":"ref_19","unstructured":"(2012, November 12). ArrayExpress \u2014 A Database of Functional Genomics Experiments. Available online: http:\/\/www.ebi.ac.uk\/arrayexpress\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41429-020-0291-8","article-title":"Antibiotics in the clinical pipeline in October 2019","volume":"73","author":"Butler","year":"2020","journal-title":"J. Antibiot."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.1128\/AAC.00839-16","article-title":"In VitroSynergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii","volume":"60","author":"Bae","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jiph.2018.07.006","article-title":"In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs","volume":"11","author":"Zhu","year":"2018","journal-title":"J. Infect. Public Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fcimb.2019.00193","article-title":"Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria","volume":"9","author":"Peyclit","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination Therapy for Treatment of Infections with Gram-Negative Bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/jac\/dkl303","article-title":"Pascual, \u00c1lvaro Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam","volume":"58","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Leite, G.C., Oliveira, M.S., Perdig\u00e3o-Neto, L.V., Rocha, C.K.D., Guimar\u00e3es, T., Rizek, C., Levin, A.S.S., and Costa, S.F. (2016). Antimicrobial Combinations against Pan-Resistant Acinetobacter baumannii Isolates with Different Resistance Mechanisms. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151270"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1128\/AAC.04089-14","article-title":"In VitroActivities of Combinations of Rifampin with Other Antimicrobials against Multidrug-Resistant Acinetobacter baumannii","volume":"59","author":"Bai","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/AAC.00367-09","article-title":"Efficacy of Rifampin and Its Combinations with Imipenem, Sulbactam, and Colistin in Experimental Models of Infection Caused by Imipenem-Resistant Acinetobacter baumannii","volume":"54","author":"Pichardo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Oliva, A., Garzoli, S., De Angelis, M., Marzuillo, C., Vullo, V., Mastroianni, C.M., and Ragno, R. (2019). In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant Acinetobacter Baumannii. Molecules, 24.","DOI":"10.3390\/molecules24050886"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/jac\/44.5.641","article-title":"In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa","volume":"44","author":"Giacometti","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00200-17","DOI":"10.1128\/AAC.00200-17","article-title":"Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741","volume":"61","author":"Corbett","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kampshoff, F., Willcox, M., and Dutta, D. (2019). A Pilot Study of the Synergy between Two Antimicrobial Peptides and Two Common Antibiotics. Antibiotics, 8.","DOI":"10.3390\/antibiotics8020060"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Geitani, R., Moubareck, C.A., Touqui, L., and Sarkis, D.K. (2019). Cationic antimicrobial peptides: Alternatives and\/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol., 19.","DOI":"10.1186\/s12866-019-1416-8"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ijantimicag.2018.10.025","article-title":"Repurposing azithromycin and rifampicin against Gram-negative pathogens by combination with peptide potentiators","volume":"53","author":"Baker","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11561","DOI":"10.1073\/pnas.1608623113","article-title":"Antimicrobial lipopeptide tridecaptin A1selectively binds to Gram-negative lipid II","volume":"113","author":"Cochrane","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1039\/C5OB00780A","article-title":"Studies on tridecaptin B 1, a lipopeptide with activity against multidrug resistant Gram-negative bacteria","volume":"13","author":"Cochrane","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00338-19","DOI":"10.1128\/AAC.00338-19","article-title":"Tridecaptin M, a New Variant Discovered in Mud Bacterium, Shows Activity against Colistin- and Extremely Drug-Resistant Enterobacteriaceae","volume":"63","author":"Jangra","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ijantimicag.2014.08.008","article-title":"Unacylated tridecaptin A1 acts as an effective sensitiser of Gram-negative bacteria to other antibiotics","volume":"44","author":"Cochrane","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"18870","DOI":"10.1038\/s41598-019-54716-8","article-title":"Purification and biological activity of natural variants synthesized by tridecaptin M gene cluster and in vitro drug-kinetics of this antibiotic class","volume":"9","author":"Jangra","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/AAC.26.4.546","article-title":"Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa","volume":"26","author":"Loh","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00092-12","article-title":"Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents","volume":"26","author":"Gonzalez","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.idc.2009.06.008","article-title":"Pharmacokinetics and Pharmacodynamics of Antibacterial Agents","volume":"23","author":"Levison","year":"2009","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/jac\/dkz034","article-title":"Eradication of persister cells of Acinetobacter baumannii through combination of colistin and amikacin antibiotics","volume":"74","author":"Chung","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/mmi.13872","article-title":"Expanding the paradigm for the outer membrane:Acinetobacter baumanniiin the absence of endotoxin","volume":"107","author":"Powers","year":"2017","journal-title":"Mol. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acsinfecdis.9b00067","article-title":"Small Molecule Potentiation of Gram-Positive Selective Antibiotics against Acinetobacter baumannii","volume":"5","author":"Martin","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1021\/acsinfecdis.0c00108","article-title":"An effective strategy targeting polymyxin-resistant Gram-negative pathogens: Polymyxin B in combination with the selective serotonin reuptake inhibitor sertraline","volume":"6","author":"Hussein","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jac\/dkm509","article-title":"Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections","volume":"61","author":"Bassetti","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jinf.2005.11.019","article-title":"Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii","volume":"53","author":"Motaouakkil","year":"2006","journal-title":"J. Infect."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dkl274","article-title":"Rifampicin\/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Saballs","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial","volume":"57","author":"Signoriello","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","first-page":"1","article-title":"Antibacterial Mechanisms of Polymyxin and Bacterial Resistance","volume":"2015","author":"Yu","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_52","unstructured":"Wayne, P. (2015). Performance Standards for Antimicrobial Susceptibility Testing: 25th Informational Supplement M100-S25, CLSI."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fmicb.2019.02153","article-title":"Microbe-Derived Indole Metabolite Demonstrates Potent Multidrug Efflux Pump Inhibition in Staphylococcus aureus","volume":"10","author":"Tambat","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10069","article-title":"Metabolite-enabled eradication of bacterial persisters by aminoglycosides","volume":"473","author":"Allison","year":"2011","journal-title":"Nature"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/14\/3255\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:49:14Z","timestamp":1760176154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/14\/3255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":54,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["molecules25143255"],"URL":"https:\/\/doi.org\/10.3390\/molecules25143255","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,17]]}}}